Precision Biosciences officer proposes $27.5K sale

The notice lists an approximate sale date of November 10, 2026 and a plan-adoption or instruction date of September 26, 2025, if relying on Rule 10b5-1.

Available on EDGAR 11/10/2026 - 10:51 AM EST Accepted by SEC EDGAR 11/10/2026 - 10:50 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Precision Biosciences Inc. (DTIL) is identified as issuer in Officer Dario J. Scimeca’s notice of a proposed sale of 2,821 common shares, with an aggregate market value of $27,516.91 and an approximate sale date of November 10, 2026. The notice lists 27,935,719 common shares outstanding. It gives September 26, 2025 as the plan-adoption or instruction date, if relying on Rule 10b5-1.

Key Figures

Proposed sale: 2,821 common shares Aggregate market value: $27,516.91 Shares outstanding: 27,935,719 common shares +2 more

5 metrics

Proposed sale 2,821 common shares Approximate sale date: November 10, 2026

Aggregate market value $27,516.91 For the common shares listed for sale

Shares outstanding 27,935,719 common shares Issuer information

Plan adoption or instruction date September 26, 2025 If relying on Rule 10b5-1

Approximate sale date November 10, 2026 Date listed for the proposed sale

Key Terms

Rule 10b5-1, ESPP Purchase, Restricted Stock Vesting

3 terms

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

ESPP Purchase financial

"Nature of Acquisition Transaction: ESPP Purchase"

Restricted Stock Vesting financial

"Nature of Acquisition Transaction: Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DTIL shares does Officer Dario J. Scimeca propose to sell?

The notice lists 2,821 common shares for sale, with an aggregate market value of $27,516.91 and an approximate sale date of November 10, 2026.

What plan date is listed for Dario J. Scimeca’s DTIL sale notice?

September 26, 2025 is listed as the plan-adoption or instruction date, if relying on Rule 10b5-1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001779581
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PRECISION BIOSCIENCES INC
SEC File Number	001-38841
Address of Issuer	302 EAST PETTIGREW STREET SUITE A-100 DURHAM NORTH CAROLINA 27701
Phone	919-314-5512
Name of Person for Whose Account the Securities are To Be Sold	Scimeca Dario
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2821	27516.91	27935719	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2020	ESPP Purchase	Issuer			69	02/28/2020	Cash
Common	08/31/2020	ESPP Purchase	Issuer			105	08/31/2020	Cash
Common	02/26/2021	ESPP Purchase	Issuer			92	02/26/2021	Cash
Common	08/31/2021	ESPP Purchase	Issuer			18	08/31/2021	Cash
Common	02/28/2022	ESPP Purchase	Issuer			68	02/28/2022	Cash
Common	06/07/2022	Restricted Stock Vesting	Issuer			731	06/07/2022	Compensation
Common	02/28/2023	ESPP Purchase	Issuer			72	02/28/2023	Cash
Common	03/03/2023	Restricted Stock Vesting	Issuer			513	03/03/2023	Compensation
Common	06/07/2023	Restricted Stock Vesting	Issuer			614	06/07/2023	Compensation
Common	11/02/2023	Restricted Stock Vesting	Issuer			331	11/02/2023	Compensation
Common	06/07/2024	Restricted Stock Vesting	Issuer			208	06/07/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Dario J. Scimeca
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)